Danaher (NYSE: DHR) reported Q1 EPS of $2.52, $0.77 better than the analyst estimate of $1.75. Revenue for the quarter came in at $6.9 billion versus the consensus estimate of $6.26 billion.

Rainer M. Blair, President and Chief Executive Officer, stated, "We had a very strong start to the year, delivering better-than-expected first quarter results across our portfolio. This broad-based outperformance was driven by double-digit core revenue growth in our base business, and our ongoing contributions to the development and production of COVID-19 vaccines, therapeutics and diagnostic tests. Our record top-line performance contributed to strong earnings per share growth and cash flow generation and, we believe, continued market share gains in many of our businesses."

For earnings history and earnings-related data on Danaher (DHR) click here.